Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?

Código QR

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?

Dimitrios A Karagiannis1, Ioannis D Ladas2, Efstratios Parikakis1, Ilias Georgalas2, Athanasios Kotsolis2, Giorgos Amariotakis1, Vasileios Soumplis1, Panagiotis Mitropoulos11Ophthalmiatrio Eye Hospital of Athens, Athens, Greece; 2First Department of Ophthalmology, Medical School of Athens University...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dimitrios A Karagiannis, Ioannis D Ladas, Efstratios Parikakis, et al.
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Age related macular degeneration Bevacizumab Ranimizumab subretinal haemorrhage Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/5b4a909ac95b4d3da9972cb7c9110698
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Subretinal Injection of Recombinant Tissue Plasminogen Activator and Gas Tamponade to Displace Acute Submacular Haemorrhages Secondary to Age-Related Macular Degeneration
por: Iannetta D, et al.
Publicado: (2021)

Location of submacular hemorrhage as a predictor of visual outcome after intravitreal ranibizumab for age-related macular degeneration
por: Karagiannis D, et al.
Publicado: (2017)

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
por: Fong AH, et al.
Publicado: (2013)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
por: Kabanarou SA, et al.
Publicado: (2017)

Inner Retinal Layer Thickness Alterations in Early Age Related Macular Degeneration in Eyes with Subretinal Drusenoid Deposits or Conventional Drusen
por: Solmaz Abdolrahimzadeh, et al.
Publicado: (2021)

Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
por: Canan H, et al.
Publicado: (2014)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa B, et al.
Publicado: (2021)

Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration
por: Michalska-Małecka K, et al.
Publicado: (2016)

Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration
por: Taipale C, et al.
Publicado: (2018)

Recent developments in age-related macular degeneration: a review
por: Al-Zamil WM, et al.
Publicado: (2017)

A case of subretinal neovascularization treated with intravitreal ranibizumab in a patient with idiopathic juxtafoveal retinal telangiectasis
por: Dimitrios Karagiannis, et al.
Publicado: (2008)

Stem cell therapies for age-related macular degeneration: the past, present, and future
por: Dang Y, et al.
Publicado: (2015)

Acquired Vitelliform Macular Degeneration: Characteristics and Challenges of Managing Subretinal Fluid
por: Joseph Juliano, et al.
Publicado: (2021)

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
por: Khanani AM, et al.
Publicado: (2019)

Lower cognitive function in patients with age-related macular degeneration: a meta-analysis
por: Zhou LX, et al.
Publicado: (2016)

Spotlight on reticular pseudodrusen
por: Rabiolo A, et al.
Publicado: (2017)

Primary treatment of diabetic macular edema
por: Tushar M Ranchod, et al.
Publicado: (2009)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
por: Dervenis N, et al.
Publicado: (2016)

Implantation of the First IMT Macular Lens in Age-Related Macular Degeneration (Literature Review)
por: M. M. Bikbov, et al.
Publicado: (2019)

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
por: Di Bartolomeo M, et al.
Publicado: (2015)

Early and intermediate age-related macular degeneration: update and clinical review
por: García-Layana A, et al.
Publicado: (2017)

The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
por: Ivanovska Adjievska B, et al.
Publicado: (2017)

The cGAS/STING pathway: a sensor of senescence-associated DNA damage and trigger of inflammation in early age-related macular degeneration
por: Wu Y, et al.
Publicado: (2019)

Gene expression levels of the insulin-like growth factor family in patients with AMD before and after ranibizumab intravitreal injections
por: Strzalka-Mrozik B, et al.
Publicado: (2017)

Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
por: Thomas BJ, et al.
Publicado: (2016)

Evaluation Of The Timing Of Intravitreal Bevacizumab Injection As Adjuvant Therapy To Panretinal Photocoagulation In Patients With Diabetic Macular Edema Secondary To Diabetic Retinopathy
por: Kartasasmita A, et al.
Publicado: (2019)

Management of neovascular age-related macular degeneration: Taiwan expert consensus
por: Ling Yeung, et al.
Publicado: (2021)

Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial
por: Gallemore RP, et al.
Publicado: (2017)

The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection
por: Suzuki H, et al.
Publicado: (2017)

Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model
por: Zhuang Cui, et al.
Publicado: (2021)

Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment
por: Pongsachareonnont P, et al.
Publicado: (2018)

Effects of Intravitreal Bevacizumab Therapy in Patients with Proliferative Diabetic Retinopathy
por: Ribeiro de Carvalho G, et al.
Publicado: (2020)

Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)
por: Horner F, et al.
Publicado: (2019)

Microcurrent stimulation in the treatment of dry and wet macular degeneration
por: Chaikin L, et al.
Publicado: (2015)

Photobiomodulation Therapy for Age-Related Macular Degeneration and Diabetic Retinopathy: A Review
por: Muste JC, et al.
Publicado: (2021)

Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study
por: Leys AM, et al.
Publicado: (2020)

Optimized Prediction Models from Fundus Imaging and Genetics for Late Age-Related Macular Degeneration
por: Arun Govindaiah, et al.
Publicado: (2021)

A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK
por: Hykin P, et al.
Publicado: (2016)

Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion
por: Kumagai K, et al.
Publicado: (2019)

Comparison between intravitreal bevacizumab and posterior sub-tenon injection of triamcinolone acetonide in macular edema secondary to retinal vein occlusion
por: Tsai MJ, et al.
Publicado: (2018)